EVOEvotec SE
Is the business good?
How good a business is EVO?
Evotec SE earns −6.1% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 15 points below what the capital costs: growth destroys value
- Operating margin
- −7.1%
Operating margin · Drug Manufacturers - Specialty & Generic median 9.5% · fiscal year to FY2025
- Share count, year on year
- +0.16%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 4.8%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | 9.7% |
| FY2021 | 6.6% |
| FY2022 | 2.8% |
| FY2023 | −6.1% |
| FY2024 | −18% |
| FY2025 | −7.1% |
Details›
- Gross marginfiscal year to FY2025
- 14%
- Operating marginfiscal year to FY2025
- −7.1%
- Net marginfiscal year to FY2025
- −13%
- Free cash flow margin
- −10%
- R&D as % of revenue
- 4.8%
- Revenue, trailing twelve months
- $788M
- Free cash flow, trailing twelve months
- −$82M
- Net income, trailing twelve months
- −$104M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −6.1%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from EVO and who it buys from, as the companies report it.
- Largest three customers43%
Combined share of revenue · FY2025 20-F
None disclosed.
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; EVO’s own figures are from its FY2025 20-F. Smaller customers and suppliers go unreported.
Drug Manufacturers, Specialty & Generic
Ranks #23 of 39 by RyuScore